CBUS Cibus, Inc.
Agricultural Chemicals · Nasdaq · SEC CIK 1705843 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY19.5%
TTM net income YoY18.8%
TTM EPS YoY46.1%
Revenue 3-yr CAGR81.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,326.7%
Net margin-2,131.4%
FCF margin-966.0%
EBITDA margin-1,243.0%
Returns
ROE-431.9%
ROA-30.6%
ROIC (approx.)-826.6%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets101.9%
Debt / equity—
Current ratio0.95x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.45x
Accruals ratio-16.8%
Payout ratio—
Capex / revenue3.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $3.64M | $4.26M |
| R&D expense | $44.20M | $50.43M |
| SG&A expense | $26.91M | $30.80M |
| Operating income | -$97.53M | -$258.40M |
| Pretax income | -$132.17M | -$282.68M |
| Income tax | $29,000 | $29,000 |
| Net income | -$127.08M | -$251.39M |
| EBITDA | -$91.61M | -$251.54M |
| EPS (basic) | -2.78 | -10.83 |
| EPS (diluted) | -2.78 | -10.83 |
| Weighted avg. shares (diluted) | 45.76M | 23.22M |
| Balance sheet | ||
| Cash & equivalents | $9.92M | $14.43M |
| Receivables | $503,000 | $1.04M |
| Current assets | $12.07M | $16.95M |
| PP&E, net | $6.30M | $11.44M |
| Goodwill | $232.52M | $253.47M |
| Intangibles | $31.68M | $33.58M |
| Total assets | $305.05M | $350.07M |
| Current liabilities | $16.86M | $19.88M |
| Short-term debt | $435,000 | $436,000 |
| Long-term debt | $93,000 | $226,000 |
| Total debt | $528,000 | $662,000 |
| Total liabilities | $283.22M | $252.24M |
| Shareholders' equity | $21.83M | $92.16M |
| Net debt | -$9.39M | -$13.77M |
| Shares outstanding | — | 29.66M |
| Cash flow statement | ||
| Operating cash flow | -$50.59M | -$58.04M |
| Capital expenditure | $578,000 | $808,000 |
| Free cash flow | -$51.17M | -$58.85M |
| Investing cash flow | -$578,000 | -$808,000 |
| Financing cash flow | $46.65M | $40.60M |
| Depreciation & amortization | $5.92M | $6.86M |
| Stock-based compensation | $8.19M | $10.75M |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.